Ceramic scaffolds enriched with gentamicin loaded poly(lactide-\emph{co}-glycolide) microparticles for prevention and treatment of bone tissue infections
PBN-AR
Instytucja
Wydział Inżynierii Materiałowej i Ceramiki (Akademia Górniczo-Hutnicza im. Stanisława Staszica w Krakowie)
Informacje podstawowe
Główny język publikacji
EN
Czasopismo
Materials Science and Engineering. C, Materials for Biological Applications
ISSN
0928-4931
EISSN
1873-0191
Wydawca
Elsevier Science BV
Rok publikacji
2016
Numer zeszytu
Strony od-do
856--864
Numer tomu
69
Link do pełnego tekstu
Identyfikator DOI
Liczba arkuszy
0.64
Autorzy
Pozostali autorzy
+ 3
Słowa kluczowe
EN
microparticles
gentamicin
PLGA
bone infections
titanium dioxide scaffolds
Streszczenia
Język
EN
Treść
Bone scaffolds are susceptible for bacterial infection when implanted, particularly in compromised bone. Therefore anti-bacterial bone scaffolds are desirable. Here a novel approach to provide bactericidal properties for titanium dioxide scaffolds is proposed. Gentamicin loaded poly(L-lactide-co-glycolide) microparticles were immobilized on the scaffold pore walls by sodium alginate hydrogel. The results show that the microparticles were effectively immobilized on the scaffolds. Desired burst release was observed within the first 8 h and gentamicin dose reached 125 μg from single scaffold that corresponded to ~25% of total drug introduced in the system. Following the initial burst, the dose was gradually decreasing up to day 10 and afterwards a sustained release of 3 μg/day was measured. Cumulatively ~90% of the drug was delivered up to day 50. Above pattern, i.e. burst release with following sustained release, is desired for prevention of perioperative bone infections: burst release stops local infections during post-implantation “decisive period” while further sustained drug release prevents bacterial recolonization. In vitro studies confirmed antimicrobial activity of released gentamicin against Staphylococcus spp. and cytocompatibility of the system with osteoblast-like cells (MG-63). Thus the system is a viable option for the treatment of bone tissue defects. © 2016 Elsevier B.V. All rights reserved.
Cechy publikacji
original article
peer-reviewed
Inne
System-identifier
idp:100469
CrossrefMetadata from Crossref logo
Cytowania
Liczba prac cytujących tę pracę
Brak danych
Referencje
Liczba prac cytowanych przez tę pracę
Brak danych